Market Overview

Leerink Swann Upgrades MedAssets To Outperform

Related MDAS
Earnings Scheduled For October 29, 2014
Top 4 NASDAQ Stocks In The Healthcare Information Services Industry With The Highest Revenue

Analysts at Leerink Swann upgraded MedAssets (NASDAQ: MDAS) from Market Perform to Outperform.

The target price for MedAssets is set to $26.

MedAssets shares have fallen 6.51% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period.

MedAssets' shares rose 0.28% to close at $21.25 yesterday.

Latest Ratings for MDAS

Dec 2014Deutsche BankMaintainsBuy
Nov 2014Raymond JamesDowngradesOutperformMarket Perform
Oct 2014JefferiesMaintainsBuy

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Leerink SwannUpgrades Analyst Ratings


Related Articles (MDAS)

Around the Web, We're Loving...

Get Benzinga's Newsletters